Affective disorders and S-adenosylmethionine: a new hypothesis.

Trends in Neurosciences
G L CantoniV Andreoli

Abstract

S-Adenosyl-L-methionine (AdoMet) is a safe and probably effective antidepressant agent in certain forms of clinical depression. This article presents a new hypothesis to account for the mechanism of action of S-adenosylmethionine in such illnesses, based upon the known biochemistry of this compound, and upon current knowledge of clinical and genetic aspects of affective disorders. Giulio Cantoni, S. Harvey Mudd and V. Andreoli postulate that at least some major mood disorders are due to abnormalities affecting the AdoMet-dependent methylation of a substance in the CNS. For convenience and without prejudging the chemical structure of this substance, they call it 'barinine'. The model requires that barinine be subject to AdoMet-dependent methylation and that methylbarinine be subject to metabolic demethylation to regenerate the original barinine. Methylbarinine should be mood elevating, whereas barinine itself should not be. Depression is a result of abnormalities lowering the normal steady-state concentration of methylbarinine, whereas mania results from an abnormal elevation of methylbarinine.

References

Jan 1, 1979·International Review of Connective Tissue Research·R C Siegel
Dec 22, 1977·The New England Journal of Medicine·J P Blass, G E Gibson
Jun 1, 1975·Metabolism: Clinical and Experimental·S H Mudd, J R Poole
Jan 1, 1986·Clinical Neuropharmacology·M W Carney
Feb 4, 1987·Nature·S HodgkinsonJ Brynjolfsson
Nov 1, 1985·Journal of Affective Disorders·R D AlarconJ R Smythies
Sep 1, 1988·The American Journal of Psychiatry·K M BellS G Potkin
Jan 15, 1988·Biochemical and Biophysical Research Communications·H SatoK Moriguchi
May 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·M W CarneyB K Toone
Jan 1, 1986·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·S D WeitmanJ J Lech
Jul 1, 1980·Pharmakopsychiatrie, Neuro-Psychopharmakologie·A KukopulosL Tondo
Jul 28, 1984·Lancet·T BottiglieriE H Reynolds
Aug 1, 1980·Metabolism: Clinical and Experimental·S H MuddC R Scriver
Jun 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·M R KehryF W Dahlquist
Mar 1, 1984·The American Journal of Psychiatry·J F LipinskiP Harris
Jan 1, 1984·Psychopharmacology·P Willner
Jan 1, 1981·Annual Review of Biochemistry·D E Koshland
Oct 1, 1982·Archives of General Psychiatry·E S GershonW E Bunney
Dec 1, 1982·Archives of General Psychiatry·M M WeissmanB A Prusoff
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ryoji YaoTetsuo Noda

❮ Previous
Next ❯

Citations

Aug 1, 1993·Pharmacology & Therapeutics·M Kotb, A M Geller
Nov 2, 1992·European Journal of Pharmacology·G MuccioliR Di Carlo
Dec 1, 1994·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C G TrolinL Oreland
Sep 24, 1999·Pharmacology, Biochemistry, and Behavior·M MiquelC M Aragon
Jan 1, 1994·Acta Neurologica Scandinavica. Supplementum·T Bottiglieri, K Hyland
Nov 17, 2009·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Edmund D HongDavid C Steffens
Sep 21, 2012·Scientific Reports·Rima Kaddurah-DaoukWayne Drevets
Sep 6, 2015·Neuropharmacology·Detlev Boison
May 20, 2015·Metabolomics : Official Journal of the Metabolomic Society·Stephen H BoyleWei Jiang
Nov 1, 1992·Molecular Biology Reports·R Smeenk, M Hylkema
Feb 15, 2002·Nutritional Neuroscience·C Prasad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.